SCHEMBL4981069

SCHEMBL4981069

C=CCc1cc(Br)ccc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.55
GABRB2 P47870 4/20 0.55
ALOX5 P09917 3/20 0.55
CNR2 P34972 2/20 0.55
ALDH1A1 P00352 2/20 0.51
PPARG P37231 1/20 0.51
PPARD Q03181 1/20 0.51
PPARA Q07869 1/20 0.51
KDM4E B2RXH2 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
MEN1 O00255 2/20 0.48
HTT P42858 2/20 0.48
KMT2A Q03164 2/20 0.48
USP2 O75604 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
ALOX15 P16050 1/20 0.48
CASP1 P29466 1/20 0.48
RECQL P46063 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4978848 0.86 PYCR1 (0.48) GABRA1GABRB2ALOX5CNR2ALDH1A1
SCHEMBL1821904 0.82 KDM4E (0.51) ALDH1A1KDM4ETDP1MEN1HTT
SCHEMBL251558 0.81 GABRA1 (0.71) GABRA1GABRB2ALOX5CNR2ALDH1A1
SCHEMBL4221328 0.81 MEN1 (0.43) GABRA1GABRB2ALOX5CNR2ALDH1A1
SCHEMBL10328509 0.80 GABRA1 (0.56) GABRA1GABRB2ALOX5CNR2ALDH1A1
SCHEMBL2848289 0.80 ALOX5 (0.56) GABRA1GABRB2ALOX5CNR2ALDH1A1
SCHEMBL21358033 0.80 GABRA1 (0.56) GABRA1GABRB2ALOX5CNR2ALDH1A1
SCHEMBL3951418 0.80 GABRA1 (0.56) GABRA1GABRB2ALOX5CNR2ALDH1A1
SCHEMBL2122024 0.79 KDM4E (0.54) ALDH1A1KDM4ETDP1MEN1HTT
SCHEMBL239781 0.79 GABRA1 (0.63) GABRA1GABRB2ALOX5CNR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives TPH1, HTR1D, HTR1B GABRA1 1636/4885GABRB2 2261/4885ALOX5 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.